Hepalink (Hong Kong) Pharmaceutical, a subsidiary of China-based pharmaceutical firm Shenzhen Hepalink, has committed $40m to a healthcare fund managed by healthcare investment fund ORI Capital, DealStreetAsia has reported.
The capital will go to ORI Healthcare Fund II, which has a $400m target for its close, according to a regulatory filing, and Hepalink intends to provide up to $40m more through a second tranche.
Shenzhen Hepalink founded Hepalink (Hong Kong) in 2010 and has also made direct corporate venture capital investments itself, its deals including a $100m series C round for UK-based antibody developer Kymab in 2016.
